Quick Answer
KalVista Pharmaceuticals, Inc. reported Stockholders Equity of $95.39 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -53.8% in Stockholders Equity from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2012 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$48.97 million | Q2 2015: $59.32 million | Q3 2015: $54.62 million | Q4 2015: $49.31 million | Q1 2016: $43.07 million | Q2 2016: $36.04 million | Q3 2016: $33.94 million | Q1 2017: $34.85 million | Q3 2017: $26.74 million | Q4 2017: $31.08 million | Q1 2018: $28.57 million | Q3 2018: $26.25 million | Q4 2018: $106.95 million | Q1 2019: $104.03 million | Q3 2019: $101.87 million | Q4 2019: $97.79 million | Q1 2020: $89.75 million | Q3 2020: $74.44 million | Q4 2020: $64.98 million | Q1 2021: $58.57 million | Q3 2021: $244.43 million | Q4 2021: $227.47 million | Q1 2022: $207.94 million | Q3 2022: $164.57 million | Q4 2022: $143.81 million | Q1 2023: $184.44 million | Q3 2023: $139.34 million | Q4 2023: $114.45 million | Q4 2023: $97.87 million | Q1 2024: $88.58 million | Q1 2024: $217.60 million | Q2 2024: $206.58 million | Q2 2024: $180.93 million | Q3 2024: $172.80 million | Q3 2024: $148.53 million | Q4 2024: $133.99 million | Q4 2024: $164.36 million | Q1 2025: $145.13 million | Q1 2025: $116.76 million | Q2 2025: $95.39 million | Q2 2025: $59.45 million | Q3 2025: $40.79 million | Q3 2025: $17.00 million.
- Over the full 16 years of available data (2012 to 2025), KalVista Pharmaceuticals, Inc.'s Stockholders Equity has grown by 437.2%.
- Historical annual values: Fiscal year 2025: $95.39 million | Fiscal year 2024: $206.58 million | Fiscal year 2023: $161.03 million | Fiscal year 2022: $185.09 million | Fiscal year 2021: $257.19 million | Fiscal year 2020: $83.75 million | Fiscal year 2019: $96.74 million | Fiscal year 2018: $27.25 million | Fiscal year 2017: $31.33 million | Fiscal year 2016: -$37.11 million | Fiscal year 2015: $49.31 million | Fiscal year 2015: -$23.56 million | Fiscal year 2014: -$44.18 million | Fiscal year 2014: -$16.21 million | Fiscal year 2013: -$33.71 million | Fiscal year 2012: -$28.29 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: